{
  "name": "nephrotoxic_medications",
  "type": "reference",
  "keywords": [
    "nephrotoxic",
    "nephrotoxicity",
    "kidney damage",
    "medication",
    "drug induced",
    "aki medication",
    "renal toxicity",
    "drug renal"
  ],
  "content": "Nephrotoxic Medications - Complete Reference:\n\n1. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):\n   - Examples: Ibuprofen, naproxen, ketorolac, indomethacin, diclofenac, celecoxib\n   - Mechanism: Inhibit prostaglandin synthesis \u2192 decreased renal perfusion\n   - Risk: Acute tubular necrosis, interstitial nephritis, papillary necrosis\n   - Higher risk with: Volume depletion, heart failure, cirrhosis, pre-existing CKD\n\n2. ACE Inhibitors and ARBs:\n   - Examples: Lisinopril, enalapril, losartan, valsartan\n   - Mechanism: Efferent arteriole dilation \u2192 decreased GFR\n   - Risk: Acute decrease in GFR, hyperkalemia\n   - Avoid: Bilateral renal artery stenosis, severe volume depletion\n\n3. Aminoglycosides:\n   - Examples: Gentamicin, tobramycin, amikacin\n   - Mechanism: Direct tubular toxicity\n   - Risk: Dose and duration dependent\n   - Monitor: Trough levels, creatinine\n\n4. Vancomycin:\n   - Mechanism: Direct tubular damage\n   - Risk: Increased with high trough levels (>20 mg/L)\n   - Higher risk when combined with other nephrotoxins\n\n5. Contrast Agents:\n   - Types: Iodinated contrast (CT, angiography)\n   - Mechanism: Contrast-induced nephropathy (CIN)\n   - Risk factors: Pre-existing CKD, diabetes, volume depletion, contrast volume\n   - Prevention: Pre-hydration with IV fluids\n\n6. Diuretics:\n   - Examples: Furosemide, hydrochlorothiazide\n   - Mechanism: Volume depletion \u2192 pre-renal AKI\n   - Risk: Excessive diuresis, electrolyte abnormalities\n\n7. Calcineurin Inhibitors:\n   - Examples: Tacrolimus, cyclosporine\n   - Used in: Transplant immunosuppression\n   - Mechanism: Vasoconstriction, chronic fibrosis\n   - Monitor: Drug levels, creatinine\n\n8. Chemotherapy Agents:\n   - Cisplatin: Direct tubular toxicity\n   - Methotrexate: Crystalline nephropathy\n   - Ifosfamide: Tubular damage\n   - Prevention: Aggressive hydration, dose adjustment\n\n9. Amphotericin B:\n   - Antifungal agent\n   - Mechanism: Direct tubular toxicity\n   - Risk: Dose dependent\n   - Liposomal forms less nephrotoxic\n\n10. Lithium:\n    - Used for: Bipolar disorder\n    - Mechanism: Chronic interstitial nephritis, nephrogenic diabetes insipidus\n    - Monitor: Lithium levels, creatinine\n\n11. Proton Pump Inhibitors (PPIs):\n    - Examples: Omeprazole, pantoprazole, esomeprazole\n    - Mechanism: Acute interstitial nephritis\n    - Risk: Usually after weeks to months of use\n\n12. Antivirals:\n    - Acyclovir: Crystalline nephropathy\n    - Tenofovir: Tubular toxicity\n    - Cidofovir: Direct tubular damage\n\nCombination Risks:\n- Triple whammy: NSAID + ACE-I/ARB + Diuretic = very high AKI risk\n- Aminoglycoside + Vancomycin = synergistic nephrotoxicity\n- Multiple nephrotoxins = cumulative risk\n\nPrevention Strategies:\n- Avoid nephrotoxins in high-risk patients when possible\n- Maintain adequate hydration\n- Monitor creatinine and electrolytes\n- Dose adjust for renal function\n- Use alternative medications when available\n- Minimize duration of nephrotoxic drugs\n\nSource: Clinical pharmacology and nephrology literature",
  "source": "Clinical pharmacology and nephrology references",
  "relevance_score": 1.0,
  "id": "extra_20251116_123853_057814"
}